These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22931905)

  • 1. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.
    Blakeley J
    Curr Opin Otolaryngol Head Neck Surg; 2012 Oct; 20(5):372-9. PubMed ID: 22931905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
    Cumpston EC; Rhodes SD; Yates CW
    Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biology of vestibular schwannomas.
    Chang LS; Welling DB
    Methods Mol Biol; 2009; 493():163-77. PubMed ID: 18839347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular biology and novel treatments of vestibular schwannomas.
    Fong B; Barkhoudarian G; Pezeshkian P; Parsa AT; Gopen Q; Yang I
    J Neurosurg; 2011 Nov; 115(5):906-14. PubMed ID: 21800959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis.
    González-Rodriguez MA; Troutman S; Bayle S; Lester DK; Grove M; Duckett D; Kareta MS; Kissil JL
    Oncogene; 2024 Sep; 43(40):2995-3002. PubMed ID: 39209965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
    Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
    J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates on Tumor Biology in Vestibular Schwannoma.
    Nourbakhsh A; Dinh CT
    Otolaryngol Clin North Am; 2023 Jun; 56(3):421-434. PubMed ID: 37121611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
    Gehlhausen JR; Park SJ; Hickox AE; Shew M; Staser K; Rhodes SD; Menon K; Lajiness JD; Mwanthi M; Yang X; Yuan J; Territo P; Hutchins G; Nalepa G; Yang FC; Conway SJ; Heinz MG; Stemmer-Rachamimov A; Yates CW; Wade Clapp D
    Hum Mol Genet; 2015 Jan; 24(1):1-8. PubMed ID: 25113746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.
    Chen J; Landegger LD; Sun Y; Ren J; Maimon N; Wu L; Ng MR; Chen JW; Zhang N; Zhao Y; Gao X; Fujita T; Roberge S; Huang P; Jain RK; Plotkin SR; Stankovic KM; Xu L
    Nat Protoc; 2019 Feb; 14(2):541-555. PubMed ID: 30617350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
    Goutagny S; Kalamarides M
    Neurochirurgie; 2018 Nov; 64(5):370-374. PubMed ID: 28162254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoglin (CD105) expression in neurofibromatosis type 2 vestibular schwannoma.
    Marioni G; Nicolè L; Cazzador D; Pavone C; D'Avella D; Martini A; Mazzoni A; Zanoletti E
    Head Neck; 2019 Oct; 41(10):3612-3617. PubMed ID: 31313389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular studies of vestibular schwannomas: a review.
    Welling DB; Packer MD; Chang LS
    Curr Opin Otolaryngol Head Neck Surg; 2007 Oct; 15(5):341-6. PubMed ID: 17823551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genesis and biology of vestibular schwannomas.
    Roche PH; Bouvier C; Chinot O; Figarella-Branger D
    Prog Neurol Surg; 2008; 21():24-31. PubMed ID: 18810196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
    Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
    Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
    Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
    J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
    Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
    Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level.
    Neff BA; Welling DB; Akhmametyeva E; Chang LS
    Otol Neurotol; 2006 Feb; 27(2):197-208. PubMed ID: 16436990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the CNS manifestations of neurofibromatosis type 2.
    Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
    Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
    Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
    Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.